Introduction: The language gap in global trials

Precision in language which determines how protocols are understood and clinical data is interpreted, is as vital as accuracy in science. In life sciences, where clinical trials span continents, accurately translating documents (clinical study protocols, informed consent forms, investigator brochures, patient report outcomes, clinical study reports) is critical at every stage. While traditional human translation processes offer high-quality results, they are time-consuming, expensive, prone to human error, apart from struggling to meet the velocity demands of modern clinical development. 

Manual translation can cost ~USD 0.12 to USD 0.40 per word, depending on language complexity and subject matter. A single pivotal clinical trial requires 200,000 to 500,000 words across  documents. Translating ~300,000 words at an average rate of USD 0.20 per word costs about USD 60,000 per language, and for ten languages, it might exceed USD 600,000.

Reports indicate that cognitive clinical translations can cost hundreds of thousands per trial, and aggregate to low millions annually for large pharma portfolios². The cost of developing a new drug exceeds ~USD 2.6 billion over 10 - 14 years and translation accounts for just 0.02% of this cost. Yet, delays can extend trial start-ups by weeks, incurring losses of ~USD 10,000 - USD 100,000 per day.^{3, 4}

The integration of AI-driven translation tools is reshaping how clinical trials are conducted globally. Neural Machine Translation (NMT), paired with domain-trained Large Language Models (LLMs), enables quick, accurate, scalable translation that can adapt to specific industry terminologies leveraging advanced algorithms. 

For instance, research at a leading cancer centre discovered that patients with limited English proficiency are less likely to participate in trials, when translation costs are not covered—suggesting that translation cost is a significant barrier to inclusion.⁵

Accurate and timely translations ensure compliance and operational efficiency and mitigate risks of delays and errors, which can significantly impact the overall cost of clinical trials. This ensures that language is not a barrier to a trial’s success – every stakeholder, from a patient in rural China to a regulator in Brazil, can access and understand the information they need in the right language.

Current Landscape: What’s unfolding? 

AI translation has moved beyond the experimental phase and is now deployed in active trials. Sponsors and contract research organizations (CRO)s are using advanced NMT and Natural Language Processing (NLP) to translate essential documents (ICF) Informed Consent Form , study protocols, questionnaires), into multiple languages, ensuring that participants from diverse linguistic backgrounds understand trial requirements. With ePRO (Electronic Patient-Reported Outcomes) adoption, AI engines can localize diary entries instantly, improving patient engagement and data quality. This hybrid approach combines machine translation with human post-editing (MTPE) workflows, achieving quality standards comparable to traditional human translation. Human reviewers focus on medical accuracy, cultural appropriateness, and regulatory compliance rather than general linguistic quality. AI handles initial drafts, and human linguists validate medical terms and region-specific legal clauses. 

Major CROs have established AI translation centers of excellence. Leading pharmaceutical companies now integrate AI translation tools, which are trained on medical and regulatory language, into their clinical operations, achieving 60-70% reduction in initial translation timeframes and improved accuracy over generic models. The FDA (The U.S. Food and Drug Administration ) and EMA (European Medicines Agency) expect patient-facing materials to be culturally and linguistically appropriate and AI helps meet these expectations faster than traditional workflows. In the European Union (EU), medical device documentation must be translated into all 24 official languages⁶ and EMA explicitly expects that ‘site-facing documents’ be available in the local language where needed.⁷

Regulatory bodies are adapting to this technological shift, signaling growing acceptance of AI translation technologies in clinical trials. The FDA's Digital Health Center of Excellence and EMA have published guidance acknowledging AI tools and draft recommendations for AI-assisted translation validation in multinational studies.^{8, 9}

Today’s leading tools provide HIPAA, ISO, and SOC-compliant translation services, leveraging transformer architectures trained on medical terminologies, delivering contextually appropriate translations. Some of the big players in this space are Amazon Translate¹⁰ with custom terminology APIs, Google Cloud Translation API, and Azure AI Translator Service¹¹. 

Companies are witnessing measurable improvements with feedback loops, glossary integration, and AI governance frameworks. Yet, challenges like medical nuances, patient comprehension, and evolving terminology remain, demanding continuous model training.

Strategy and recommendations: Building a robust AI translation pipeline

To harness AI translation effectively, life sciences companies should adopt a structured strategy. 

• Use Domain-specific AI models: Domain-specific NMT models, trained on clinical trial terminologies and regulatory languages, help address the medical nuances that generic tools often miss. For instance, Named Entity Recognition (NER) models identify medical terminology, drug names, and procedure codes that require specialized handling.

• Adopt a human-in-the-loop model: AI translation should complement and not replace human expertise. For patient diaries and eCOA instruments needing psychometric validation, AI translation can accelerate initial translations, while linguistic validation must include cognitive debriefing with native speakers to ensure speed, compliance, and quality.

• Regulatory compliance: Organizations must establish AI translation governance frameworks addressing data privacy, quality, and regulatory compliance. Maintaining audit trails, version control, reviewer annotations, and using tools that support ISO 17100 and GDPR compliance are recommended to protect patient data.

• Monitoring quality with AI metrics: Automated checks like BLEU (Bilingual Evaluation Understudy) ) scores and semantic similarity metrics help with pre-screening translations before human review and identify segments that may distort clinical meaning or regulatory language, ensuring higher accuracy and prioritizing expert validation.

• Integrating translation management systems (TMS): TMS platforms automate and manage translation workflows and support glossary management, style guide enforcement, quality scoring, and reviewer feedback to ensure consistency across materials.

• Feedback loops for model improvement: Post-edit feedback mechanisms can retrain models to adapt to therapeutic areas, local regulations, and cultural nuances.

Barriers and success stories

Adoption isn't without hurdles. Data privacy, especially under GDPR (General Data Protection Regulation )and HIPAA( Health Insurance Portability and Accountability Act of 1996 ), restricts the use of cloud-based AI tools and complicates AI translation deployment by ensuring stringent controls over processing and storing of sensitive clinical data. Integration with existing systems can also be slow, especially in legacy-heavy pharma environments, while many clinical teams resist AI translation due to accuracy concerns. Moreover, regulatory skepticism remains high in some regions. Without robust validation, AI-translated materials may face pushbacks from ethics committees.

On the other hand, success stories are growing. A leading decentralized clinical trial platform partnered with a global language services provider on an oncolytic immunotherapy trial for a mid-pharma company, spanning eight locales to streamline translation in clinical trials, using AI-enabled workflow. This cut translation timelines by 43%, enabling faster trial activation and reduced manual coordination costs significantly¹².

A global CRO deployed a life sciences engine across twenty trials, reporting a 40% drop in translation costs and 25% acceleration in site activations. Another sponsor trained a GPT-4 model on oncology trial texts, achieving 96% translation accuracy after three iterations. Similarly, a top pharma company used the AI-human hybrid model to translate ICFs across twelve languages in under two weeks, reducing translation time by 60% and improving patient enrollment.

These examples show that with the right strategy, AI translation delivers measurable impact.

Conclusion: The road ahead

Global clinical trials inherently require managing multiple languages across diverse regions. From start-up to close-out, there are critical documents that must be translated to satisfy regulatory laws, ethical standards, and practical communication needs.

AI translation represents a transformative opportunity for CROs seeking to accelerate global study execution while controlling costs. Technology has matured beyond experimental applications to become enterprise-ready infrastructure for pharmaceutical development. Organizations that strategically implement hybrid AI-human translation workflows will gain competitive advantages in patient recruitment and regulatory submission timelines.

The immediate future will see increased regulatory acceptance of AI translation technologies, particularly for non-patient-facing documents like study protocols. Success requires thoughtful implementation combining technological capabilities with human expertise, robust quality assurance processes, and clear regulatory compliance frameworks¹³. Early adopters are already realizing significant benefits, positioning themselves advantageously for the next phase of global clinical development. 

References

1. https://translated.com/resources/healthcare-translation-services-cost-medical-documentation-budget-guide
2. https://www.grandviewresearch.com/industry-analysis/life-sciences-translation-services-market-report
3. https://www.appliedclinicaltrialsonline.com/view/tufts-center-study-drug-development-cost-developing-new-drugs
4. https://www.appliedclinicaltrialsonline.com/view/how-much-does-a-day-of-delay-in-a-clinical-trial-really-cost-
5. https://pmc.ncbi.nlm.nih.gov/articles/PMC11046417/#:~:text=Ensuring%20that%20trial%20participants%20are,differ%20from%20those%20who%20participate.
6. https://www.ema.europa.eu/en/about-us/about-website/languages-website
7. https://www.clinicalstudies.in/ensuring-ecrf-usability-in-multi-lingual-trials/
8. https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-artificial-intelligence-ai-medicinal-product-lifecycle_en.pdf
9. https://www.ema.europa.eu/en/documents/other/guiding-principles-use-large-language-models-regulatory-science-medicines-regulatory-activities_en.pdf
10. https://aws.amazon.com/blogs/machine-learning/translate-documents-in-real-time-with-amazon-translate/ 
11. https://learn.microsoft.com/en-us/azure/ai-foundry/responsible-ai/translator/transparency-note?view=foundry-classic
12. https://www.clinicalleader.com/doc/case-study-removing-translation-bottlenecks-with-ai-0001
13. https://magazine.hms.harvard.edu/articles/what-will-it-take-translate-ai-research-clinical-advances